USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS

摘要

Provided herein are methods of reducing neoplastic progenitor cell proliferation and alleviating associated symptoms in individuals diagnosed with or considered to have an osteoproliferative disorder, such as essential thrombocythemia (ET). Also provided herein are methods of using telomerase inhibitors to maintain blood platelet counts in a relatively normal range in the blood of a subject diagnosed with or suspected of having a myeloproliferative disorder, such as ET. .